Kaiser Permanente Georgia
Atlanta, Georgia, 30309, United States
NCT Number: NCT05735340
Diabetes distress has been identified as one of the largest contributors to the racial disparity in glycemic control that disproportionately burdens Black patients ages 18-30 years with type 1 diabetes (T1D). In order to combat this issue, this study assesses the feasibility of the culturally tailored intervention T1DES and evaluates the effect of the T1DES intervention on diabetes outcomes in a pilot randomized clinical trial among Black young adults with T1D.
Looking for future studies?
Notify Me18 year–30 year
All sexes
Interventional
Not applicable
Atlanta, Georgia, 30309, United States
This research focuses on the unique needs of Black young adults aged 18-30 years to address a critical gap in the research and clinical care. The goal is to test the feasibility and preliminary efficacy of a culturally adapted and tailored intervention to enhance diabetes management strategies among Black young adults with T1D, addressing the pervasive racial disparity in health outcomes for this population.
The specific aims for this study are to:
Aim 1: Assess feasibility of the culturally tailored intervention T1DES by measuring intervention acceptability, demand (retention, completed > 80% of sessions), practicality, and implementation fidelity through participant surveys and key informant interviews with participants and the health care delivery team.
Aim 2: Evaluate the effect of the T1DES intervention on diabetes outcomes in a pilot randomized clinical trial among N=40 Black young adults age 18-30 years with T1D and elevated HbA1c (>7.5%) by comparing changes in HbA1c, diabetes distress, and self-management from baseline to 6-months post-baseline among participants randomized to T1DES compared to the diabetes education-only control condition.
The goal of this study is to provide diabetes education and emotion regulation support tailored for Black young adults' experiences that will result in sustained glycemic control and can be incorporated into adult endocrinology practices.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants in this arm will receive traditional diabetes education over 5 sessions in the first 3 months of participation and be followed for 6 months.
Participants in this arm will receive the T1DES behavioral interventions over 5 sessions in the first 3 months of participation and be followed for 6 months.
Time frame: 3 months
Problem Areas in Diabetes - Emerging Adults 25 Item Measure and Scoring. Higher scores indicate more diabetes distress, with a range from 0 to 100.
Time frame: 6 months
Problem Areas in Diabetes - Emerging Adults 25 Item Measure and Scoring. Higher scores indicate more diabetes distress, with a range from 0 to 100.
Time frame: 3 months
Type 1 Diabetes Distress Scale. Higher scores indicate more diabetes distress, with a range from 1 to 6.
Time frame: 6 months
Type 1 Diabetes Distress Scale. Higher scores indicate more diabetes distress, with a range from 1 to 6.
Time frame: 3 months
Point of Care A1C
Time frame: 6months
Point of Care A1C
Kaiser Permanente
Other
Evaluating the Feasibility of Type 1 Diabetes Education and Support Intervention to Improve Diabetes Distress Among Black Young Adults
Acronym: T1DES
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06420518
Diabetes Mellitus, Endocrine System Diseases
Montreal, Quebec, Canada
View Trial DetailsNCT03973827
Autoimmune Diseases, Diabetes Mellitus
Huddinge, Sweden
View Trial DetailsNCT03912012
Autoimmune Diseases, Diabetes Mellitus
Bron, France
View Trial DetailsNCT05678712
Diabetes Mellitus, Endocrine System Diseases
Aalborg, Denmark
View Trial Details